查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863374

骨髓恶性肿瘤检测市场：依技术、应用、最终用户、检体类型和检测模式划分－2025-2032年全球预测

Hematologic Malignancies Testing Market by Technology, Application, End User, Sample Type, Test Mode - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，骨髓恶性肿瘤检测市场将成长至 67.3 亿美元，复合年增长率为 8.10%。

关键市场统计数据
基准年 2024 36亿美元
预计年份：2025年 39亿美元
预测年份 2032 67.3亿美元
复合年增长率 (%) 8.10%

本书提供了一个简洁而权威的框架，阐述了诊断创新、临床需求和实验室现代化如何重塑骨髓恶性肿瘤检测路径。

骨髓恶性肿瘤检测处于快速发展的生物学、精准诊断和不断变化的临床工作流程的交汇点。分子谱分析的最新进展，以及细胞遗传学和免疫表型分析能力的提升，正在改变诊断路径并深化诊断分类。随着临床医生和实验室负责人努力提供更快、更具指导意义的检测结果，实验室生态系统也在积极回应，建构日益整合的平台和扩充性的检测组合，涵盖传统和先进的检测方式。

因此，检测流程不再分散，而是整合到多种诊断模式中，从而为治疗方案选择、风险分层和微量残存疾病监测提供依据。自动化和资讯科学领域的变革性创新正在推动更高的检测通量和更好的数据整合，同时，对品管和法规遵循的需求也在不断影响实验室的实施策略。总而言之，这些趋势凸显了当前诊断环境的特征：临床价值取决于分析效能、营运效率以及将复杂数据转化为清晰治疗决策点的能力。

技术融合、营运现代化和分散式检查模式正在从根本上改变诊断实​​践和商业性模式。

骨髓恶性肿瘤的检测格局正经历着变革性的转变，这主要得益于技术的融合、临床模式的转变以及支付者和监管机构期望的不断变化。分子诊断，特别是基于定序的检测方法，正越来越多地与细胞遗传学和流式细胞技术联合应用，以产生多维度的诊断结果。同时，免疫组织化学检测方法也在不断改进，以适应液体和组织样本的检测，从而支持互补性生物标记的评估，提高诊断的准确性，并有助于标靶治疗的选择。

同时，实验室运作正透过自动化、标准化通讯协定和云端资料平台现代化，促进机构间的安全协作。加上血液和骨髓检体处理技术的改进，这些变革缩短了检测结果的获取时间，同时提高了诊断准确性。此外，在某些情况下，就地检验的兴起促使製造商和临床实验室重新思考检测设计，以提高其稳健性和分散化程度。这些融合的趋势正在推动新型服务模式的诞生，重塑供应商伙伴关係，并拓展基于价值的诊断策略的机会。

本文基于实证分析，探讨了2025年美国已实施或提案的关税对诊断实验室供应链、采购经济效益和业务连续性的影响。

美国拟于2025年实施或提案的关税将对骨髓恶性肿瘤检测价值链产生复杂影响，波及试剂供应、设备采购以及进口耗材的经济效益。对诊断组件征收关税可能会增加检测设备和一次性试剂的本地到货成本，迫使采购负责人重新谈判供应商合约、寻找替代货源或加强与本地製造商的合作。因此，依赖跨境供应关係的实验室可能需要重新评估其库存策略，并投资于更长前置作业时间的采购计划，以维持服务的连续性。

此外，关税可能会加速供应链区域化，并鼓励对关键试剂和一次性耗材的国内生产能力进行投资。然而，这种转变需要时间和资金，而这些资源可能不足以满足少数全球製造商生产的专用组件的需求。从监管和合约角度来看，实验室和供应商也需要重新评估定价模式和报销谈判，以反映成本结构的变化。简而言之，2025年的关税趋势将成为供应链多元化、营运紧急时应对计画以及采购策略与临床服务交付承诺更加紧密结合的催化剂。

综合細項分析揭示了技术模式、临床适应症、临床环境、检体处理流程和检测方式如何共同作用，从而确定诊断优先顺序。

基于细分市场的洞察凸显了诊断能力与临床需求在技术、应用领域、终端使用者、检体类型和检测模式等方面的交集。基于技术的诊断领域涵盖细胞遗传学、流式细胞技术、免疫组织化学和分子诊断。在细胞遗传学领域，萤光原位杂合反应(FISH) 和核型分析仍是结构突变和非整倍体检测的核心技术。同时，免疫组织化学涵盖了用于细胞抗原分析的液相和组织学方法。分子诊断进一步细分为：用于靶向位点的萤光杂合反应、用于全面突变分析的次世代定序以及用于灵敏检测的聚合酵素链锁反应，从而形成一个支持诊断准确性的多层次套件。

应用主导的需求主要集中在白血病、淋巴瘤、多发性骨髓瘤和骨髓发育不良症候群，每种疾病都有其独特的生物标记和监测要求，因此需要特定的检测方法和工作流程。包括学术研究机构、医院/诊所和实验室在内的终端用户正在以不同的强度和规模采用这些方法，从而影响自动化和资讯整合方面的投资。检体类型主要围绕血液和骨髓，这决定了分析前处理和检测方法的选择。同时，检测模式将工作流程划分为实验室环境和照护现场环境，从而影响週转时间预期和分散化策略。总而言之，这种細項分析突显了技术选择、临床应用案例和医疗保健环境之间的交集，并明确了检测方法开发、实验室实施和商业性合作的优先事项。

一份详细的区域评估报告，分析了基础设施、报销和製造能力如何推动全球市场中差异化的引入和商业化策略。

骨髓恶性肿瘤检测的区域趋势反映了各主要地区在医疗基础设施、报销机制、法规环境和创新能力方面的差异。在美洲，机构网络和参考实验室往往主导先进分子和细胞遗传学检测的普及，这主要得益于竞争格局的推动，该格局强调集中式实验室和高通量/综合检测组合。相较之下，欧洲、中东和非洲地区（EMEA）既有成熟的卓越中心，也存在着更为受限的环境，其检测普及受到国家报销政策和地区特定监管路径的影响，因此需要量身定制的部署策略和伙伴关係模式。

亚太地区都市区正迅速采用诊断创新技术。这主要得益于临床检测量的成长、实验室自动化投资的增加以及国内製造业的扩张，从而减少了对进口的依赖。在亚太地区，互通性、人才培养和供应链稳健性仍然是跨领域的优先事项，它们将决定新型检测方法被纳入常规临床实践的速度。因此，希望扩大检测解决方案规模的相关人员必须根据每个区域市场的具体需求调整商业化、监管和支援模式，同时利用过渡性合作来加速普及和能力建设。

公司层面的策略分析表明，平台整合商、专业分子诊断创新商和服务实验室正在重塑竞争定位和伙伴关係模式。

骨髓恶性肿瘤检测领域的企业级趋势显示，成熟的诊断公司、新兴的分子诊断企业和专业服务实验室三者构成了平衡的模式。大型诊断设备製造商持续投资于平台整合、工作流程自动化和检测项目扩展，以满足医院网路和高通量参考实验室的需求。同时，规模较小的分子诊断公司则专注于小众检测组合、先进的定序工作流程和生物资讯能力，以推动精准医疗的应用。仪器製造商与专业试剂公司之间的策略联盟日益普遍，由此产生的整合解决方案能够减少操作摩擦，并加速实验室采用这些解决方案。

服务型实验室透过不断扩展的检测项目、快速的结果报告以及咨询解读服务来脱颖而出，从而协助临床医生处理复杂病例。同时，它们的商业策略强调价值验证，显示诊断数据如何有助于改善治疗方案、减少后续资源消耗以及促进与支付者的互动。因此，那些将强大的分析能力、可靠的实施支援、本地监管专业知识和灵活的商业模式相结合的公司，更有能力满足不同医疗机构的需求，并应对不断变化的临床需求。

为实验室管理人员和诊断供应商提供切实可行的、优先排序的建议，以建立供应链韧性、数位整合和临床协作，从而实现永续应用。

行业领导者应优先制定一套连贯的行动计划，以平衡短期业务连续性和长期能力建设。首先，供应链多元化并与供应商密切合作将有助于降低关税和物流风险。实验室和供应商应携手合作，梳理关键组件的依赖关係，并尽可能建立冗余采购和本地製造伙伴关係。其次，应专注于投资自动化和资讯科学，以减少人工操作环节，并实现可扩展的解读工作流程，整合细胞遗传学、流式细胞技术、免疫组织化学和分子数据，从而确保临床报告的一致性。

此外，各机构应加强与临床实验室的合作，以调整其检测项目，使其适应白血病、淋巴瘤、多发性骨髓瘤和骨髓发育不良症候群不断变化的治疗模式。这将确保检体处理和结果报告能够满足临床医生的需求。最后，采用灵活的商业模式，例如按绩效付费服务、捆绑式解决方案以及基于订阅的参考资料访问，将有助于实验室和供应商向支付方和医疗服务提供者展现其价值。总而言之，要维持卓越的诊断水平，有效的领导力需要在采购、技术、临床整合和商业性创新等方面进行协调一致的投资。

本研究采用的调查方法是透明的混合方法，结合了关键相关人员访谈、技术检验和背景分析，以得出稳健、可操作的结论。

本分析的调查方法采用多源混合方法，结合了对实验室主任、临床专家、采购人员和行业高管的访谈，以及对监管指南、技术检验文献和上市公司资讯披露的系统性回顾。数据综合强调对供应商声明、实验室实践和临床指南进行三角验证，以确保观察结果反映的是实际营运情况，而非供应商的立场。定性研究结果辅以案例研究，这些案例研究涉及在血液和骨髓检体中以及在实验室检测和就地检验模式之间部署综合检测策略的实验室。

在整个研究过程中，我们始终专注于验证有关检测效能、检体处理和工作流程检验的技术声明，并以同行评审文献和共识诊断框架为依据。调查方法优先考虑资讯来源的透明度，并运用结构化分析来识别发展趋势、风险因素（例如关税影响）以及对最终用户（包括学术机构、医院和参考调查方法）的实际影响。这种将相关人员的见解、技术检验和背景分析结合的严谨方法，为决策者得出切实可行的结论奠定了基础。

简洁扼要的结论强调了整合诊断、供应链韧性和策略商业化将如何决定临床影响和营运永续性。

总之，骨髓恶性肿瘤检测正在发展成为一个整合的多模态生态系统，细胞遗传学、流式细胞技术、免疫组织化学和分子诊断技术在此融合，提供更丰富、更具临床指导意义的见解。实验室和供应商必须应对诸多挑战，例如关税、监管复杂性和不同地区采用模式带来的供应链变化，同时还要投资于自动化、互通性和以临床医生为中心的报告系统。白血病、淋巴瘤、多发性骨髓瘤和骨髓发育不良症候群技术的融合和日益增长的需求，为优先考虑临床效用和运营扩充性的差异化解决方案创造了机会。

展望未来，相关人员，将更有利于加速临床应用。透过强调健全的采购体系、完善的检验流程和灵活的商业模式，产业相关人员可以将诊断技术的进步转化为更优质的患者照护和永续的实验室运作。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 透过整合人工智慧驱动的数位病理平台实现血液肿瘤诊断自动化
  • 利用次世代定序扩大白血病管理中微量残存疾病监测的范围
  • 推出液态生物检体检测方法
  • 开发照护现场流式细胞技术仪
  • 用于同时检测多种骨髓恶性肿瘤标记的多重基因组检测板的商业化
  • 监管核准流程将加速CAR-T细胞疗法伴随诊断的商业化
  • 製药公司与诊断实验室合作，共同开发针对血液肿瘤的标靶治疗检测方法。
  • 建立远距病理网络，以改善资源匮乏地区获得专业血液病理学审查服务的机会

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依技术分類的骨髓恶性肿瘤检测市场

  • 细胞遗传学
    • 萤光原位杂合反应
    • 核型分析
  • 流式细胞技术
  • 免疫组织化学
    • 液态
    • 组织
  • 分子诊断
    • 萤光原位杂合反应
    • 次世代定序
    • 聚合酵素链锁反应

第九章 按应用分類的骨髓恶性肿瘤检测市场

  • 白血病
  • 淋巴瘤
  • 多发性骨髓瘤
  • 骨髓发育不良症候群

第十章骨髓恶性肿瘤检测市场（依最终用户划分）

  • 学术和研究机构
  • 医院和诊所
  • 参考检验机构

第十一章 依标本类型分類的骨髓恶性肿瘤检体市场

  • 血
  • 骨髓

第十二章骨髓恶性肿瘤检测市场（依检测方法划分）

  • 实验室
  • 护理点

第十三章 各地区骨髓恶性肿瘤检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章骨髓恶性肿瘤检测市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国骨髓恶性肿瘤检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Becton, Dickinson and Company
    • Siemens Healthineers AG
    • QIAGEN NV
    • Illumina, Inc.
    • Bio-Rad Laboratories, Inc.
    • Myriad Genetics, Inc.
Product Code: MRR-2E76C3E47FC1

The Hematologic Malignancies Testing Market is projected to grow by USD 6.73 billion at a CAGR of 8.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.60 billion
Estimated Year [2025] USD 3.90 billion
Forecast Year [2032] USD 6.73 billion
CAGR (%) 8.10%

A concise and authoritative framing of how diagnostic innovation, clinical demand, and laboratory modernization are reshaping hematologic malignancy testing pathways

Hematologic malignancies testing sits at the intersection of rapidly evolving biology, precision diagnostics, and shifting clinical workflows. Recent advances in molecular profiling, coupled with enhanced cytogenetic and immunophenotyping capabilities, have transformed diagnostic pathways and deepened the granularity of diagnostic classifications. As clinicians and laboratory leaders seek to deliver faster, more actionable results, the laboratory ecosystem has responded with increasingly integrated platforms and more scalable assay portfolios that span traditional and advanced modalities.

Consequently, testing workflows are no longer siloed; they converge across multiple diagnostic modalities to inform treatment selection, risk stratification, and minimal residual disease monitoring. Transitional innovations in automation and informatics facilitate higher throughput and better data harmonization, while parallel needs for quality management and regulatory compliance continue to shape laboratory adoption strategies. Taken together, these dynamics underscore a diagnostic environment in which clinical value is driven by analytic performance, operational efficiency, and the ability to translate complex data into clear therapeutic decision points.

How technological convergence, operational modernization, and decentralized testing models are fundamentally transforming diagnostic practices and commercial approaches

The landscape for hematologic malignancies testing is experiencing transformative shifts driven by technological convergence, changing clinical paradigms, and evolving payer and regulatory expectations. Molecular diagnostics, particularly sequencing-based assays, are increasingly deployed alongside cytogenetics and flow cytometry to create multidimensional diagnostic readouts. At the same time, immunohistochemistry practices have adapted to liquid and tissue formats to support complementary biomarker assessment, enhancing diagnostic certainty and supporting targeted therapy selection.

In parallel, laboratory operations are undergoing modernization through automation, standardized protocols, and cloud-enabled data platforms that enable secure cross-institutional collaboration. Together with improvements in sample processing for blood and bone marrow, these changes reduce time to result while increasing diagnostic resolution. Moreover, the shift toward point-of-care testing in select scenarios is prompting manufacturers and clinical labs to rethink assay design for robustness and decentralization. These converging trends are catalyzing new service models, reshaping vendor partnerships, and expanding opportunities for value-based diagnostic strategies.

An evidence-based analysis of how 2025 United States tariff actions are reshaping supply chains, procurement economics, and operational resilience for diagnostic laboratories

United States tariff measures enacted or proposed in 2025 introduce complex implications for the hematologic malignancies testing value chain, affecting the economics of reagent supply, instrument procurement, and imported consumables. Tariffs on diagnostic components can increase landed costs for laboratory instrumentation and single-use reagents, which in turn pressures procurement managers to renegotiate supplier contracts, explore alternative sourcing, or accelerate local manufacturer engagement. Consequently, laboratories that rely on cross-border supply relationships may need to revise inventory strategies and invest in longer-lead planning to maintain service continuity.

Furthermore, tariffs can spur accelerated regionalization of supply chains and encourage investment in domestic manufacturing capacity for critical reagents and disposables. However, this shift requires time and capital, and it may not address specialized components produced by a limited number of global manufacturers. From a regulatory and contracting perspective, laboratories and vendors must also reassess pricing models and reimbursement negotiations to reflect altered cost structures. In short, tariff dynamics in 2025 act as a catalyst for supply chain diversification, operational contingency planning, and closer alignment between purchasing strategies and clinical service commitments.

Integrated segmentation analysis revealing how technology modalities, clinical indications, care settings, sample workflows, and testing modes align to define diagnostic priorities

Segmentation-centric insights illuminate where diagnostic capability and clinical demand intersect across technologies, applications, end users, sample types, and test modes. Based on technology, the diagnostic landscape includes cytogenetics, flow cytometry, immunohistochemistry, and molecular diagnostics; within cytogenetics, both fluorescence in situ hybridization and karyotyping remain central to structural variant and aneuploidy detection, while immunohistochemistry spans liquid-based and tissue-based approaches to cellular antigen profiling. Molecular diagnostics further breaks down into fluorescence in situ hybridization for targeted loci, next-generation sequencing for comprehensive mutational landscapes, and polymerase chain reaction for focused, high-sensitivity detection, creating a layered toolkit that supports diagnostic precision.

Application-driven demand concentrates on leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes, each presenting distinct biomarker and monitoring requirements that favor particular testing modalities and workflows. End users such as academic and research institutes, hospitals and clinics, and reference laboratories adopt these modalities with differing intensity and scale, influencing investments in automation and informatics integration. Sample type considerations center on blood and bone marrow, which dictate pre-analytical handling and assay selection, while test mode divides workflows into laboratory-based and point-of-care environments, shaping turnaround expectations and decentralization strategies. Altogether, segmentation analysis highlights where technology choices, clinical use cases, and care settings converge to define priorities for assay development, laboratory deployment, and commercial engagement.

A nuanced regional assessment detailing how infrastructure, reimbursement, and manufacturing capacity drive differentiated adoption and commercialization strategies across global markets

Regional dynamics in hematologic malignancies testing reflect differences in healthcare infrastructure, reimbursement frameworks, regulatory environments, and capacity for innovation across major geographies. In the Americas, institutional networks and reference laboratories often lead in adopting advanced molecular and cytogenetic testing, supported by centralized labs and a competitive vendor landscape that emphasizes throughput and comprehensive assay portfolios. By contrast, Europe, Middle East & Africa exhibit a heterogeneous mix of mature centers of excellence and constrained settings where adoption is influenced by national reimbursement decisions and region-specific regulatory pathways, prompting tailored rollout strategies and partnership models.

Asia-Pacific demonstrates rapid uptake of diagnostic innovation in urban centers, driven by growing clinical volumes, investments in laboratory automation, and expanding domestic manufacturing that can reduce dependence on imports. Across regions, interoperability, workforce training, and supply chain robustness remain cross-cutting priorities that determine how quickly new assays translate into routine clinical practice. Consequently, stakeholders seeking to scale testing solutions must adapt commercialization, regulatory, and support models to the nuanced needs of each geographic market while leveraging transitional collaborations to accelerate access and capability building.

Strategic company-level analysis showing how platform consolidation, specialized molecular innovators, and service labs are reshaping competitive positioning and partnership models

Company-level dynamics in hematologic malignancies testing show a balance between established diagnostics firms, emerging molecular players, and specialized service laboratories. Leading diagnostics manufacturers continue to invest in platform consolidation, workflow automation, and assay breadth to serve hospital networks and high-volume reference labs, while smaller molecular diagnostics firms focus on niche panels, advanced sequencing workflows, and bioinformatics capabilities that enable precision medicine applications. Strategic partnerships between instrument providers and reagent specialists are increasingly common, creating bundled solutions that reduce operational friction and accelerate laboratory onboarding.

Service laboratories are differentiating through expanded test menus, faster reporting, and consultative interpretive services that support clinicians in complex cases. At the same time, commercial strategies emphasize value demonstration-showing how diagnostic data improves treatment selection, reduces downstream utilization, and supports payer conversations. As a result, companies that combine robust analytical performance with strong implementation support, local regulatory expertise, and flexible commercial models are better positioned to capture demand in diverse care settings and to respond to evolving clinical needs.

Practical and prioritized recommendations for laboratory leaders and diagnostic vendors to build supply resilience, digital integration, and clinical alignment for sustained adoption

Industry leaders should prioritize a coherent set of actions that balance near-term operational continuity with long-term capability building. First, supply chain diversification and close supplier collaboration will mitigate tariff and logistics risks; laboratories and vendors should jointly map critical component dependencies and establish redundant sourcing or local manufacturing partnerships where feasible. Second, investments in automation and informatics should be targeted to reduce manual touchpoints and enable scalable interpretation workflows that integrate cytogenetic, flow, immunohistochemical, and molecular data for coherent clinical reporting.

Moreover, organizations should strengthen clinical-laboratory partnerships to align test menus with evolving treatment paradigms across leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes, ensuring that sample handling and turnaround commitments meet clinician needs. Finally, adopting flexible commercial models-such as outcome-linked services, bundled solutions, and subscription-based access to reference data-will help laboratories and vendors demonstrate value to payers and providers. In sum, actionable leadership requires coordinated investments across procurement, technology, clinical integration, and commercial innovation to sustain diagnostic excellence.

A transparent mixed-methods research approach combining primary stakeholder interviews, technical validation, and contextual analysis to ensure robust and actionable conclusions

The research methodology underpinning this analysis employed a multi-source, mixed-methods approach combining primary interviews with laboratory directors, clinical specialists, procurement leaders, and industry executives alongside a systematic review of regulatory guidance, technical validation literature, and public company disclosures. Data synthesis emphasized triangulation to reconcile supplier statements, laboratory practice patterns, and clinical guidelines, ensuring that observations reflect operational realities rather than vendor positioning. Qualitative insights were augmented by case studies that illustrate how laboratories deploy integrated testing strategies across blood and bone marrow specimens and across laboratory-based and point-of-care testing modes.

Throughout the research process, care was taken to validate technical claims regarding assay performance, sample handling, and workflow integration against peer-reviewed literature and consensus diagnostic frameworks. The methodology prioritized transparency in source attribution and applied structured analysis to identify directional trends, risk factors such as tariff impacts, and practical implications for end users including academic centers, hospitals, and reference laboratories. This rigorous combination of stakeholder insight, technical validation, and contextual analysis supports actionable conclusions for decision-makers.

A succinct conclusion emphasizing how integrated diagnostics, supply resilience, and strategic commercialization will determine clinical impact and operational sustainability

In conclusion, hematologic malignancies testing is evolving into an integrated, multimodal ecosystem where cytogenetics, flow cytometry, immunohistochemistry, and molecular diagnostics converge to provide richer, clinically actionable insights. Laboratories and vendors must navigate tariff-driven supply chain shifts, regulatory complexities, and heterogeneous regional adoption patterns while investing in automation, interoperability, and clinician-focused reporting. The convergence of technologies and growing demand across leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes create opportunities for differentiated solutions that prioritize clinical utility and operational scalability.

Looking ahead, stakeholders who align their product development, commercialization, and operational strategies with the nuanced needs of academic and research institutes, hospitals and clinics, and reference laboratories will be best positioned to accelerate clinical impact. By emphasizing resilient sourcing, robust validation, and flexible commercial models, industry players can translate diagnostic advancements into improved patient care pathways and sustainable laboratory operations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven digital pathology platforms for automated blood cancer diagnostics
  • 5.2. Expansion of minimal residual disease monitoring using next-generation sequencing in leukemia management
  • 5.3. Adoption of liquid biopsy assays for non-invasive monitoring of treatment response in lymphoma patients
  • 5.4. Development of point-of-care flow cytometry devices for rapid immunophenotyping in resource-limited settings
  • 5.5. Commercialization of multiplexed genomic panels for simultaneous detection of multiple hematologic malignancy biomarkers
  • 5.6. Regulatory approval pathways accelerating commercialization of CAR T cell therapy companion diagnostics
  • 5.7. Partnerships between pharmaceutical companies and diagnostic labs to co-develop targeted therapy assays in blood cancers
  • 5.8. Implementation of telepathology networks to improve access to expert hematopathology review in underserved regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hematologic Malignancies Testing Market, by Technology

  • 8.1. Cytogenetics
    • 8.1.1. Fluorescence In Situ Hybridization
    • 8.1.2. Karyotyping
  • 8.2. Flow Cytometry
  • 8.3. Immunohistochemistry
    • 8.3.1. Liquid Based
    • 8.3.2. Tissue Based
  • 8.4. Molecular Diagnostics
    • 8.4.1. Fluorescence In Situ Hybridization
    • 8.4.2. Next Generation Sequencing
    • 8.4.3. Polymerase Chain Reaction

9. Hematologic Malignancies Testing Market, by Application

  • 9.1. Leukemia
  • 9.2. Lymphoma
  • 9.3. Multiple Myeloma
  • 9.4. Myelodysplastic Syndromes

10. Hematologic Malignancies Testing Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Hospitals & Clinics
  • 10.3. Reference Laboratories

11. Hematologic Malignancies Testing Market, by Sample Type

  • 11.1. Blood
  • 11.2. Bone Marrow

12. Hematologic Malignancies Testing Market, by Test Mode

  • 12.1. Laboratory Based
  • 12.2. Point Of Care

13. Hematologic Malignancies Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hematologic Malignancies Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hematologic Malignancies Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Danaher Corporation
    • 16.3.4. Thermo Fisher Scientific Inc.
    • 16.3.5. Becton, Dickinson and Company
    • 16.3.6. Siemens Healthineers AG
    • 16.3.7. QIAGEN N.V.
    • 16.3.8. Illumina, Inc.
    • 16.3.9. Bio-Rad Laboratories, Inc.
    • 16.3.10. Myriad Genetics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HEMATOLOGIC MALIGNANCIES TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HEMATOLOGIC MALIGNANCIES TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEMATOLOGIC MALIGNANCIES TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY KARYOTYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LIQUID BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TISSUE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY LABORATORY BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-